Shanghai Seventh People's Hospital Successfully Completes China’s First Clinical Cases Using Xuanyu Medical’s RhythPulse® Pulsed Field Ablation System
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue words to follow us
ENTERPRISE
Recently, the Department of Cardiology at Shanghai Seventh People's HospitalDirector Lu YangUnder the leadership of,Professor Jiang Nianxin, Professor Jiang Bing, in collaboration with the anesthesia department and medical team, successfully applied ShineyoMedical's RhythPulse®Pulsed Field Ablation Catheter Successfully Performs Pulsed Field Ablation (PFA) for Two Patients with Atrial Fibrillation. This procedure is among the first batch in China to use ShineyoMedical's RhythPulse.®The clinical application of pulsed ablation marks a new breakthrough in the cardiology department of our hospital, which has mastered another safe, efficient, and precise interventional technology in the field of arrhythmia treatment. This achievement represents a significant advancement in the interventional diagnosis and treatment of cardiovascular diseases and comprehensive atrial fibrillation management capabilities.
Surgical Procedure
After a comprehensive preoperative evaluation, no significant abnormalities were found in the atrial structure of the two patients, and there was no thrombus in the left atrium, which met the indications for atrial fibrillation pulsed field ablation (PFA). After the patients and their families were fully informed and agreed, it was decided to perform RhythPulse.®Pulsed Electric Field Ablation Surgery.
Preoperative CT 3D reconstruction of the left atrium was performed to evaluate the anatomical morphology and ostial diameter of the pulmonary veins in detail. Based on the imaging measurements, ShineyoMedical's RhythPulse was selected.®The systematic guidewire model 20mm pulsed ablation catheter was used for mapping and ablation. The surgeries for both patients were performed under general anesthesia. The femoral vein was punctured to establish surgical access, mapping electrodes were placed, and the atrial septal puncture (with a slightly lower and anterior puncture site) was successfully completed under DSA guidance, establishing access to the left atrium. After completing angiography of the left and right pulmonary veins, the RhythPulse®The PFA catheter was delivered to the left upper pulmonary vein along the steerable sheath, and ablation was performed in the ostial and vestibule regions, successfully eliminating the pulmonary vein potentials and achieving isolation. Subsequently, ablation was carried out sequentially on the left lower, right upper, and right lower pulmonary veins, successfully completing bilateral pulmonary vein electrical isolation. The overall ablation process took approximately 40 minutes. The surgery proceeded smoothly without any intraoperative complications. The patient's vital signs remained stable, and they were safely returned to the ward post-operation.
Preoperative CT
Left Upper Pulmonary Vein Ablation
Disappearance of the Left Upper Pulmonary Vein Potential
Left Inferior Pulmonary Vein Ablation
Disappearance of the Left Lower Pulmonary Vein Potential
Right Upper Pulmonary Vein Ablation
Disappearance of the Right Upper Pulmonary Vein Potential
Ablation of the Right Lower Pulmonary Vein
Disappearance of the Right Lower Pulmonary Vein Potential
The successful implementation of pulsed ablation surgery under general anesthesia marks another significant breakthrough for the cardiology department in the field of arrhythmia, especially in atrial fibrillation ablation and interventional treatment. It also demonstrates the strength of our hospital's multidisciplinary collaboration in ensuring the smooth execution of surgeries. Going forward, our hospital will continue to promote high-quality medical services to safeguard the health of residents in the district.
Expert Profile
Lu Yang
Shanghai Seventh People's Hospital
Director of Cardiology, Associate Chief Physician, Master's Supervisor
Yan Shi-Yun, inheritor of the National Master of Traditional Chinese Medicine, Standing Committee Member of the Cardiovascular Disease Special Committee of the Pudong New Area Medical Association in Shanghai, Member of the Chinese Association of Traditional Chinese Medicine Branch, Deputy Chairman of the Third Committee of the Brain and Heart Treatment Special Committee of the Pudong New Area Medical Association in Shanghai, Member of the Valve and Structural Center Working Group of the Second Committee of the Cardiovascular Internal Medicine Physician Branch of the Shanghai Physicians Association, Member of the Chronic Total Occlusion Intervention Treatment Club (CTOCC), Member of the "Old Buddies" Team, Certified Independent Operator of ADR and Coronary Rotablation, Youth Editorial Board Member of the Chinese Journal of Interventional Cardiology.
Expert Clinic: Monday morning, Wednesday afternoon, Thursday morning, Friday morning
Jiang Nianxin
Shanghai Seventh People's Hospital
Associate Chief Physician, Chief Diagnostician Group Leader, Cardiac Electrophysiology Group Leader, Master's Graduate Supervisor.
Expertise: Diagnosis and treatment of cardiovascular critical conditions such as arrhythmia, hypertension, and coronary heart disease. Specializes in cardiac electrophysiology, with expertise in radiofrequency ablation for tachyarrhythmias, performing nearly 200 radiofrequency ablation surgeries annually. Academic Achievements: Recipient of the Seventh People's Hospital of Shanghai's Rising Star and Beidouxing Talent Cultivation Program funding. Current Academic Positions: Committee Member of the First Interventional Cardiology Branch of the Shanghai Traditional Chinese Medicine Association; Youth Committee Member of the Cardiovascular Specialty Committee of the Pudong New Area Medical Association; Committee Member of the Electrocardiogram Specialty Committee of the Pudong New Area Medical Association; Committee Member of the Pudong New Area Atrial Fibrillation Center (Special Disease) Alliance; Committee Member of the Second Professional Committee of Brain and Heart Treatment of the Pudong New Area Medical Association.
Expert Clinic: Monday all day, Tuesday morning
Jiang Bing
Shanghai Seventh People's Hospital
Deputy Chief Physician of Cardiology, Master's Degree
Proficient in the diagnosis and treatment of common cardiovascular diseases, such as arrhythmia, coronary heart disease, hypertension, and heart failure, with extensive experience in the diagnosis and treatment of critical cardiovascular conditions. Specializes in pacing and electrophysiology, focusing on radiofrequency ablation interventional therapy for tachyarrhythmias. Principal investigator of two projects: one at the Pudong New Area level and another at the hospital level. Youth Committee Member of the Shanghai Pudong New Area Medical Association Professional Committee; Youth Committee Member of the Shanghai Pudong New Area Brain-Heart Treatment Specialized Committee; Committee Member of the Shanghai Pudong New Area Electrocardiogram Specialized Committee; Member of the Cardiac Rhythm Branch (SHRS) of the Shanghai Biomedical Engineering Society; Member of the Electrophysiology Female Physicians Association.
Expert Clinic: Wednesday morning, Saturday morning
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, mainly used for treating rapid arrhythmias such as drug-refractory and recurrent atrial fibrillation. Its core advantages include:
Large Focal Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing the ablation efficiency by more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.
Clinical Validation Excellence:In the clinical trial of 151 cases, the immediate success rate was 100%, and the success rate of atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving internationally leading standards.
